Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1802 Combined With Camrelizumab and Famitinib in Advanced Solid Tumors
NCT05208177Phase 2Terminated
- Sponsor
- Hengrui
- Start
- Apr 2022
- Primary completion
- Aug 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1802 in solid tumor (advanced stage), sponsored by Hengrui. Started Apr 2022; status: terminated.
02
Drugs
SHR-1802
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT05208177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05208177.